In young women, combined oral contraceptives don't raise risk of macromastia: Research

Oct 01, 2022

New Delhi, Oct 01 (ANI): A study published in the October issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons, found that combined oral contraceptives (COCs) containing both oestrogen and progestin do not contribute to the development of enlarged breasts (macromastia), nor do they increase the risk of breast regrowth in adolescents and young women following breast-reduction surgery (ASPS). Doctors are recommended to investigate COCs for young ladies suffering from macromastia. Breast reduction surgery, also known as reduction mammaplasty, is an effective treatment for adolescents and women with macromastia that reduces pain and psychosocial issues. The most common type of hormonal contraception is combined oral contraceptives (HCs). COCs are used to treat a variety of diseases in adolescents, including acne, menstrual irregularities, endometriosis, and polycystic ovary syndrome, in addition to their contraceptive benefits.